Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.
68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for pancreatic cancer
Aged between 18 and 75 years (inclusive); [+4]
Patients with other clearly diagnosed malignant tumours; [+4]
This clinical trial is a single-center, open-label, non-randomized first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary efficacy of SNA028 (which is a two-step radioactivity pretargeting agents conducted by GPA33-CC and 177Lu-SmartD2) in patients with GPA33-positive colorectal cancer who have experienced disease progression/recurrence following prior standard therapy.
Age range of 18 to 75 years old (including boundary values); [+14]
Poor nutritional status and inability to tolerate the test subjects; [+9]
This clinical trial is a single-center, open-label, non-randomized, first-in-human (FIH), dose-escalation study evaluating the safety, tolerability, and preliminary efficacy of 177Lu-DOTA-SNA040 in patients with advanced Claudin18.2-positive solid tumors (e.g., gastric cancer, gastroesophageal junction adenocarcinoma, pancreatic cancer, cholangiocarcinoma, etc.) who have disease progression following first-line therapy.
Age range of 18 to 75 years old (including boundary values); [+5]
The nutritional status is extremely poor, with a BMI of less than 18.5 during sc... [+10]
68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for gastric or gastroesophageal junction
Age range of 18 to 75 years old (including boundary values); [+4]
Uncontrolled severe infections or individuals with other serious illnesses; [+3]